What is the preoperative management for a patient with rheumatoid arthritis (RA) in clinical remission, taking Methotrexate (MTX) 7.5 mg/week and Deflazacort (corticosteroid) 6 mg alternate days, undergoing fracture neck of femur repair?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Preoperative Management of RA Patient on Methotrexate and Deflazacort for Femoral Neck Fracture Repair

Methotrexate Management

Continue methotrexate 7.5 mg weekly through surgery without interruption. 1

  • The 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline conditionally recommends continuing methotrexate at the usual dose through elective orthopedic surgery, based on low to moderate quality evidence. 1

  • Continuing methotrexate actually decreases infection risk (RR 0.39,95% CI 0.17-0.91) compared to discontinuation, while also reducing the risk of disease flares (RR 0.06,95% CI 0.0-1.10). 1

  • The elimination half-life of methotrexate is only 1-2 hours, so stopping it immediately before surgery provides no measurable benefit. 2

  • This recommendation applies to both elective and urgent orthopedic procedures, including fracture repair. 1

Glucocorticoid (Deflazacort) Management

Continue deflazacort 6 mg on alternate days through surgery at the current dose—do not administer supraphysiologic "stress doses." 1

  • The 2022 ACR/AAHKS guideline conditionally recommends continuing the current daily dose of glucocorticoids rather than administering supraphysiologic doses on the day of surgery. 1

  • This patient is on a low dose (6 mg alternate days, equivalent to approximately 5 mg prednisone alternate days), which is below the threshold typically requiring stress-dose supplementation. 1

  • The traditional practice of stress-dose steroids lacks strong evidence and may increase perioperative complications without clear benefit. 1

Preoperative Assessment

Verify disease remission status and assess for infection or other contraindications to proceeding with current medications: 3

  • Confirm complete blood count is adequate (WBC >3.5×10^9/L, neutrophils >2×10^9/L). 2, 4

  • Check liver function tests (transaminases should be <2× upper limit of normal). 2, 4, 3

  • Assess renal function with creatinine clearance calculation (should be >20 mL/min for methotrexate continuation). 2

  • Rule out active infection requiring antibiotics, which would necessitate temporary methotrexate discontinuation. 2, 4

Postoperative Medication Resumption

Resume methotrexate immediately when oral intake recommences after surgery. 5, 2

  • If methotrexate was held for any reason perioperatively, restart once wound shows evidence of healing, sutures/staples are removed, there is no significant swelling/erythema/drainage, and no ongoing infection (typically ~14 days). 1

  • Continue deflazacort at the same alternate-day dosing postoperatively. 1

  • Monitor for signs of infection and temporarily cease methotrexate only if postoperative infection develops requiring antibiotics. 2

Important Caveats

  • This patient's RA is in clinical remission, which supports medication continuation—active disease or severe comorbidities might alter the risk-benefit calculation. 1

  • Fracture neck of femur repair, while urgent, follows the same perioperative medication principles as elective total hip arthroplasty per ACR guidelines. 1

  • The low methotrexate dose (7.5 mg/week) and minimal corticosteroid exposure (6 mg alternate days) represent relatively low immunosuppression, further supporting continuation. 1, 6

  • Ensure folic acid supplementation (minimum 5 mg weekly) is maintained perioperatively to reduce methotrexate-related toxicity. 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Methotrexate Management in the Inpatient Setting

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Methotrexate Interruption in Rheumatoid Arthritis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Perioperative Management of Biologics and DMARDs for Back Surgery

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Methotrexate for treating rheumatoid arthritis.

The Cochrane database of systematic reviews, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.